Intervention Review

Glutamatergic drugs for schizophrenia

  1. Jari Tiihonen1,
  2. Kristian Wahlbeck2,*

Editorial Group: Cochrane Schizophrenia Group

Published Online: 19 APR 2006

Assessed as up-to-date: 10 FEB 2006

DOI: 10.1002/14651858.CD003730.pub2


How to Cite

Tiihonen J, Wahlbeck K. Glutamatergic drugs for schizophrenia. Cochrane Database of Systematic Reviews 2006, Issue 2. Art. No.: CD003730. DOI: 10.1002/14651858.CD003730.pub2.

Author Information

  1. 1

    University of Kuopia, Department of Forensic Psychiatry, Helsinki, Finland

  2. 2

    THL National Institute for Health and Welfare, Department of Mental Health and Substance Abuse Services, Helsinki, Finland

*Kristian Wahlbeck, Department of Mental Health and Substance Abuse Services, THL National Institute for Health and Welfare, PO Box 220, Helsinki, FIN-00531, Finland. kristian.wahlbeck@thl.fi. kristian.wahlbeck@helsinki.fi.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 19 APR 2006

SEARCH

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Oliver Gruber, Antonella Chadha Santuccione, Helmut Aach, Magnetic Resonance Imaging in Studying Schizophrenia, Negative Symptoms, and the Glutamate System, Frontiers in Psychiatry, 2014, 5,

    CrossRef

  2. 2
    Jonathan C Ipser, Candice Sander, Alon Seifan, Dan J Stein, Augmentation of psychotherapy with d-cycloserine for anxiety disorders, The Cochrane Library,